The case for plant-made veterinary immunotherapeutics

Edward Topp, Rebecca Irwin, Tim McAllister, Martin Lessard, Jussi J. Joensuu, Igor Kolotilin, Udo Conrad, Eva Stöger, Tsafrir Mor, Heribert Warzecha, Chris J. Hall, Michael D. McLean, Eric Cox, Bert Devriendt, Andrew Potter, Ann Depicker, Vikram Virdi, Larry Holbrook, Ketan Doshi, Marike Dussault & 5 others Robert Friendship, Oksana Yarosh, Han Sang Yoo, Jacqueline MacDonald, Rima Menassa

Research output: Contribution to journalReview ArticleScientificpeer-review

13 Citations (Scopus)

Abstract

The excessive use of antibiotics in food animal production has contributed to resistance in pathogenic bacteria, thereby triggering regulations and consumer demands to limit their use. Alternatives for disease control are therefore required that are cost-effective and compatible with intensive production. While vaccines are widely used and effective, they are available against a minority of animal diseases, and development of novel vaccines and other immunotherapeutics is therefore needed. Production of such proteins recombinantly in plants can provide products that are effective and safe, can be orally administered with minimal processing, and are easily scalable with a relatively low capital investment. The present report thus advocates the use of plants for producing vaccines and antibodies to protect farm animals from diseases that have thus far been managed with antibiotics; and highlights recent advances in product efficacy, competitiveness, and regulatory approval.
Original languageEnglish
Pages (from-to)597-604
JournalBiotechnology Advances
Volume34
Issue number5
DOIs
Publication statusPublished - 2016
MoE publication typeA2 Review article in a scientific journal

Fingerprint

Animal Diseases
Vaccines
Anti-Bacterial Agents
Domestic Animals
Economics
Bacteria
Costs and Cost Analysis
Food
Antibodies
Proteins

Keywords

  • antibiotic resistance
  • antibody
  • immunotherapeutic
  • livestock production
  • molecular farming
  • plant biotechnology
  • recombinant protein
  • veterinary vaccine

Cite this

Topp, E., Irwin, R., McAllister, T., Lessard, M., Joensuu, J. J., Kolotilin, I., ... Menassa, R. (2016). The case for plant-made veterinary immunotherapeutics. Biotechnology Advances, 34(5), 597-604. https://doi.org/10.1016/j.biotechadv.2016.02.007
Topp, Edward ; Irwin, Rebecca ; McAllister, Tim ; Lessard, Martin ; Joensuu, Jussi J. ; Kolotilin, Igor ; Conrad, Udo ; Stöger, Eva ; Mor, Tsafrir ; Warzecha, Heribert ; Hall, Chris J. ; McLean, Michael D. ; Cox, Eric ; Devriendt, Bert ; Potter, Andrew ; Depicker, Ann ; Virdi, Vikram ; Holbrook, Larry ; Doshi, Ketan ; Dussault, Marike ; Friendship, Robert ; Yarosh, Oksana ; Yoo, Han Sang ; MacDonald, Jacqueline ; Menassa, Rima. / The case for plant-made veterinary immunotherapeutics. In: Biotechnology Advances. 2016 ; Vol. 34, No. 5. pp. 597-604.
@article{16ae24d18ab14bca9852b29f31567d81,
title = "The case for plant-made veterinary immunotherapeutics",
abstract = "The excessive use of antibiotics in food animal production has contributed to resistance in pathogenic bacteria, thereby triggering regulations and consumer demands to limit their use. Alternatives for disease control are therefore required that are cost-effective and compatible with intensive production. While vaccines are widely used and effective, they are available against a minority of animal diseases, and development of novel vaccines and other immunotherapeutics is therefore needed. Production of such proteins recombinantly in plants can provide products that are effective and safe, can be orally administered with minimal processing, and are easily scalable with a relatively low capital investment. The present report thus advocates the use of plants for producing vaccines and antibodies to protect farm animals from diseases that have thus far been managed with antibiotics; and highlights recent advances in product efficacy, competitiveness, and regulatory approval.",
keywords = "antibiotic resistance, antibody, immunotherapeutic, livestock production, molecular farming, plant biotechnology, recombinant protein, veterinary vaccine",
author = "Edward Topp and Rebecca Irwin and Tim McAllister and Martin Lessard and Joensuu, {Jussi J.} and Igor Kolotilin and Udo Conrad and Eva St{\"o}ger and Tsafrir Mor and Heribert Warzecha and Hall, {Chris J.} and McLean, {Michael D.} and Eric Cox and Bert Devriendt and Andrew Potter and Ann Depicker and Vikram Virdi and Larry Holbrook and Ketan Doshi and Marike Dussault and Robert Friendship and Oksana Yarosh and Yoo, {Han Sang} and Jacqueline MacDonald and Rima Menassa",
year = "2016",
doi = "10.1016/j.biotechadv.2016.02.007",
language = "English",
volume = "34",
pages = "597--604",
journal = "Biotechnology Advances",
issn = "0734-9750",
publisher = "Elsevier",
number = "5",

}

Topp, E, Irwin, R, McAllister, T, Lessard, M, Joensuu, JJ, Kolotilin, I, Conrad, U, Stöger, E, Mor, T, Warzecha, H, Hall, CJ, McLean, MD, Cox, E, Devriendt, B, Potter, A, Depicker, A, Virdi, V, Holbrook, L, Doshi, K, Dussault, M, Friendship, R, Yarosh, O, Yoo, HS, MacDonald, J & Menassa, R 2016, 'The case for plant-made veterinary immunotherapeutics', Biotechnology Advances, vol. 34, no. 5, pp. 597-604. https://doi.org/10.1016/j.biotechadv.2016.02.007

The case for plant-made veterinary immunotherapeutics. / Topp, Edward; Irwin, Rebecca; McAllister, Tim; Lessard, Martin; Joensuu, Jussi J.; Kolotilin, Igor; Conrad, Udo; Stöger, Eva; Mor, Tsafrir; Warzecha, Heribert; Hall, Chris J.; McLean, Michael D.; Cox, Eric; Devriendt, Bert; Potter, Andrew; Depicker, Ann; Virdi, Vikram; Holbrook, Larry; Doshi, Ketan; Dussault, Marike; Friendship, Robert; Yarosh, Oksana; Yoo, Han Sang; MacDonald, Jacqueline; Menassa, Rima (Corresponding Author).

In: Biotechnology Advances, Vol. 34, No. 5, 2016, p. 597-604.

Research output: Contribution to journalReview ArticleScientificpeer-review

TY - JOUR

T1 - The case for plant-made veterinary immunotherapeutics

AU - Topp, Edward

AU - Irwin, Rebecca

AU - McAllister, Tim

AU - Lessard, Martin

AU - Joensuu, Jussi J.

AU - Kolotilin, Igor

AU - Conrad, Udo

AU - Stöger, Eva

AU - Mor, Tsafrir

AU - Warzecha, Heribert

AU - Hall, Chris J.

AU - McLean, Michael D.

AU - Cox, Eric

AU - Devriendt, Bert

AU - Potter, Andrew

AU - Depicker, Ann

AU - Virdi, Vikram

AU - Holbrook, Larry

AU - Doshi, Ketan

AU - Dussault, Marike

AU - Friendship, Robert

AU - Yarosh, Oksana

AU - Yoo, Han Sang

AU - MacDonald, Jacqueline

AU - Menassa, Rima

PY - 2016

Y1 - 2016

N2 - The excessive use of antibiotics in food animal production has contributed to resistance in pathogenic bacteria, thereby triggering regulations and consumer demands to limit their use. Alternatives for disease control are therefore required that are cost-effective and compatible with intensive production. While vaccines are widely used and effective, they are available against a minority of animal diseases, and development of novel vaccines and other immunotherapeutics is therefore needed. Production of such proteins recombinantly in plants can provide products that are effective and safe, can be orally administered with minimal processing, and are easily scalable with a relatively low capital investment. The present report thus advocates the use of plants for producing vaccines and antibodies to protect farm animals from diseases that have thus far been managed with antibiotics; and highlights recent advances in product efficacy, competitiveness, and regulatory approval.

AB - The excessive use of antibiotics in food animal production has contributed to resistance in pathogenic bacteria, thereby triggering regulations and consumer demands to limit their use. Alternatives for disease control are therefore required that are cost-effective and compatible with intensive production. While vaccines are widely used and effective, they are available against a minority of animal diseases, and development of novel vaccines and other immunotherapeutics is therefore needed. Production of such proteins recombinantly in plants can provide products that are effective and safe, can be orally administered with minimal processing, and are easily scalable with a relatively low capital investment. The present report thus advocates the use of plants for producing vaccines and antibodies to protect farm animals from diseases that have thus far been managed with antibiotics; and highlights recent advances in product efficacy, competitiveness, and regulatory approval.

KW - antibiotic resistance

KW - antibody

KW - immunotherapeutic

KW - livestock production

KW - molecular farming

KW - plant biotechnology

KW - recombinant protein

KW - veterinary vaccine

U2 - 10.1016/j.biotechadv.2016.02.007

DO - 10.1016/j.biotechadv.2016.02.007

M3 - Review Article

VL - 34

SP - 597

EP - 604

JO - Biotechnology Advances

JF - Biotechnology Advances

SN - 0734-9750

IS - 5

ER -